ProteoSep® 2D ProteinMicroarray Executive

OverviewDesigned for Drug Hunters and Clinicians

Why Consider Our Proteomics Module?• Easy to insert, at any point, in your drug discovery process.• Designed to generate unique, clinically important data much earlier in the clinical trial

decision making process.• A “Bedside to Bench” approach to drug and clinical biomarker development• A simple means of discovering what we do not know using real patient samples

• Find high probability targets for any disease of interest.• Patient autoantibody signatures serve as the sentinels for targets of interest• Model cell lines serve as the source of targets instead of recombinant proteins – More real protein

expression information utilized.• Clinical relevance of data dictates better/best path forward new and/or existing targets

• Concept works for Biologics and Biosimilars development applications as well.Low cost, precise and fast

High Throughput Process-TBI Example

Culture 10 million cells (highly pure)

Human Neurons Human Astroglia

Detach and Centrifuge to

Pellets

Human Microglia

Processing TBI Patient Samples

100s of Patient Samples (Serum) Provided by

Program Sponsor

Proteostep 2DLiquid Fractionation

App. 2,000 Protein Samples for Arraying

Microarray Printing

Production of Required # of Arrays for Testing Samples

Only a Small Fraction of Samples Prove Clinically

Valid

Cell Lysates

Projects• TBI – 2 projects underway - Confidential• Pain Management - Confidential• Breast cancer – Univ. of Michigan Medical center• Liver cancer/Liver disease – University of Chicago Hospitals• Pancreatic Cancer/Pancreatitis – Univ. of Mich.• Colorectal Cancer - Henry Ford Hospital• Prostate Cancer – University of Michigan• HCP and Biologics development - various companies - confidential

How the Results Can be Used• Drug clinical trial monitoring in parallel to clinical outcome.• Drug treated patients from non-drug treated patients (both sick).• Drug responders from non-responders.• Disease progression (stage, grade, etc. as well as temporal changes).• Identifying differences between cancer and a chronic condition (liver

disease from liver cancer, pancreatitis from pancreatic cancer, etc.)• Population proteomics (before and after exposure – e.g. soldiers

being deployed or worker exposure)• Biologics/Biosimilars purity monitoring and clinical development

Highlights• Protein spots that differentiate the patient populations of interest are

identified (typically < 5% of the total number of spots on the microarray).• The <5% spots can be readily accessed for more detailed analysis of

the proteins present for validation and further research.• Now, biologically important candidate biomarkers are pinpointed before

resorting to more sophisticated techniques.

Low cost, precise and fast

Neuromics’ hStem and Primary Cell Categories• Cancer-Associated Fibroblasts (CAFs) and Cells• Brain Astrocytes• Cardiomyocytes-New• Chondrocytes-New• Endothelial Cells-New• Fibroblasts-New• hNP1™ Human Neural Progenitor & • hN2™ Neuron Discovery Kits• NeuroNet Pure Human Neurons Discovery and HTS Kits• Osteoblasts-New• hMPro™ Human Mesenchymal Progenitors (hMPCs)• Mesenchymal Stem Cells (hMSCs)

Pete ShusterCEO and OwnerDirect Phone: 612-801-1007pshuster@neuromics.com